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Spence JD, Coates V, Li H, et al. Arch Neurol 2010;67:180-6.
Conclusion: Less than 5% of patients with asymptomatic carotid
stenosis will benefit from revascularization. Patients with asymptomatic
carotid stenosis should receive intensive medical therapy and only be con-
sidered for revascularization if microemboli are demonstrated by transcranial
Doppler (TCD) imaging.
Summary: The principle cardiovascular event in patients with asymp-
tomatic carotid stenosis is myocardial infarction rather than stroke (Stroke
1994;25:759-65). Randomized trials have demonstrated a reduction in late
stroke with carotid endarterectomy for asymptomatic high-grade carotid
stenosis, with a high number needed to treat to prevent one stroke. In
addition, the benefit of surgery in these trials occurred in an era of less
intense medical therapy than what is prevalent now. The authors previously
reported that TCD detection of microemboli is useful in identifying patients
with asymptomatic carotid stenosis who might be candidates for revascular-
ization. The authors noted, however, that patients with asymptomatic
carotid stenosis with detectable microemboli by TCD have become fewer in
number in the last few years. They hypothesized that the incidence of
microemboli has been reduced through a possible mechanism of stabiliza-
tion of carotid plaques with more intensive medical therapy.
This study was designed to compare the proportion of asymptomatic
carotid stenosis patients with TCD-determined microemboli, cardiovascular
events, and carotid plaque progression correlated with baseline medical
therapy before and after 2003. The study involved 468 patients collected
prospectively with asymptomatic carotid stenosis 60% as determined by
duplex scanning. Of the 468 patients, 199 were enrolled between January 1,
2000, and December 31, 2002, and 269 were enrolled between January
2003 and July 2007. Before 2003, microemboli were present in 12.6% and
since 2003 were present in only 3.7% (P  .001). Declining numbers of
patients withmicroemboli correlated with better control of plasma lipids and
slower progression of carotid plaque area. Before 2003, 17.6% of patients
had stroke, death, myocardial infarction, or carotid endarterectomy for
symptoms. Since 2003, only 5.6% have had stroke, death, myocardial
infarction, or carotid endarterectomy for symptoms (P  .001). In the first
year of follow-up before 2003, the rate of carotid plaque progression
declined from 69 mm2 (standard deviation, 96 mm2) to 23 mm2 (standard
deviation, 86 mm2, P  .001) after 2003.
Comment: The tone of this article is clearly biased against intervention
of any sort for high-grade asymptomatic carotid stenosis. The literature cited
by the authors for stroke rates with asymptomatic carotid stenosis treated by
endarterectomy or carotid stenting are on the very high end of the published
ranges. Nevertheless, the authors are probably correct that modern medical
management of patients with asymptomatic carotid stenosis likely by itself
lowers the potential benefit of intervention added to medical management.
The current approach for management of patients with high-grade asymp-
tomatic carotid stenosis in the United States is essentially to offer interven-
tion to most patients based on the presence of a duplex-detected high-grade
stenosis. This approach is coming under increasing question and scrutiny
and is certainly not the approach used throughout much of the world
outside the United States. There is currently no agreement on how to best
select these patients for intervention. The authors suggest screening with
TCD, and others suggest using magnetic resonance characteristics of the
plaque or even ultrasound plaque characterization. It seems unlikely that
another large randomized trial of intervention vs no intervention for asymp-
tomatic carotid stenosis will be conducted and completed anytime in the
near future. For now, selection of patients with asymptomatic carotid
stenosis for intervention will likely remain center-specific and confined
primarily to the United States.
Factors that Predict Risk of Thrombosis in Relatives of Patients with
Unprovoked Venous Thromboembolism
Couturaud F, Leroyer C, Julian JA. Chest 2009;136:1537-45.
Conclusion:Unprovoked venous thromboembolism (VTE) occurring
at a young age is associated with increased risk of VTE in families of patients
with VTE.
Summary: About one-quarter of all VTE is idiopathic or “unpro-
voked.” One-third of these patients will have identified genetic predisposi-
tions to thrombosis. The factor V-Leiden and G20210A prothrombin gene
mutations account for 90% of detected genetic abnormalities (Lancet 2003;
138:19-25). If a genetic mutation is not identified in a patient with VTE, it
is often assumed that relatives do not have increased risk of thrombosis. Such
1584an assumption may not be true, however, because it is likely there are many
causes of heredity thrombophilia that have yet to be discovered. The
authors’ primary hypothesis was at the risk of VTE would be similar in
families of patients who had factor V-Leiden or the G20210A prothrombin
gene mutation compared with relatives of patients with neither of these two
abnormalities. The authors assumed that most patients with unprovoked
VTE, who have negative tests for thrombophilia, do in fact have hereditary
defects that have yet to be discovered and that these abnormalities would
increase the risk of thrombosis in the patient’s first-degree relatives.
This was a cross-sectional study. Investigators were blinded to whether
patients or their relatives had thrombophilia. The prevalence of previous
venous VTE in 1916 first-degree relatives of 348 unselected patients with a
first episode of unprovoked VTE was investigated. Patient characteristics
and the presence of factor V-Leiden or the G20210A prothrombin gene
mutation was assessed as predictors of VTE in the patient’s first-degree
relatives.
The first-degree relatives had sustained 102 previous episodes of VTE
(prevalence 5.3%). Patient thrombosis at a young age was the strongest
predictor of VTE in relatives. There was an odds ratio (OR) of 3.27 (95%
confidence interval [CI], 1.68-6.38) for younger patients (patients aged
45 when VTE occurred; lowest quartile) compared with older patients
(patients aged 71; highest quartile). The presence of factor V-Leiden or
G20210A prothrombin gene mutation was a weak independent predictor of
VTE in relatives (adjusted OR, 1.48; 95% CI, 0.94-2.33).
Comment: The data indicate that the age of patients with unprovoked
VTE is probably the single best way to stratify the risk of VTE in those
patients’ families. Testing for factor V-Leiden or the G20210A prothrombin
gene mutation in a patient with unprovoked VTE has limited ability to
predict VTE in first-degree relatives. The data also provide indirect evidence
that there are undiscovered hereditary thrombophilic abnormalities in many
patients with unprovoked VTE.
“Hybrid” Repair of Aneurysms of the Transverse Aortic Arch: Mid-
term Results
Hughes GC, Daneshmand MA, Balsara KR, et al. Ann Thorac Surg 2009;
88:1882-8.
Conclusion: Hybrid repair of transverse aortic arch aneurysms at
midterm follow-up is safe and effective.
Summary: A combination of endovascular and open surgical ap-
proaches to the treatment of transverse arch aneurysms has been described
(Ann Thorac Surg 2008;86:1524-9; J Thorac Cardiovasc Surg 2008;136:
21-8). Potential advantages of the hybrid approach include lower perioper-
ative morbidity and mortality and single-stage treatment of some patholo-
gies that previously required a two-stage repair. At the authors’ institution
betweenMarch 2005 andOctober 2008, 178 thoracic endograft procedures
were performed, of which 28 (16%) were hybrid arch repairs. Indications
included saccular aneurysm (n 11) and fusiform aneurysm (n 17) of the
transverse arch. The aneurysm in 10 patients (36%) was secondary to aortic
dissection in patients with 2 cm of proximal landing zone distal to the
innominate artery. In these cases, a right-to-left carotid-carotid bypass was
performed to create a proximal landing zone covering the left carotid origin.
For 12 patients with mid arch aneurysms and 2 cm of proximal landing
zone in the ascending aorta, proximal ascending aorta-based arch debranch-
ing was performed. In patients with arch aneurysms without an adequate
proximal landing zone were with an adequate distal landing zone, a one-
stage elephant trunk procedure was used to create a proximal landing zone.
Procedures were staged in the group receiving an initial elephant trunk
procedure but were performed at the same setting in the other two groups.
The mean patient age was 64  13 years. Technical success was achieved in
100%. The 30-day and in hospital death, stroke, and permanent paraplegia
paresis rates were 0%, 0% and 3.6%, respectively. No late aortic related events
have occurred at a mean follow-up of 14  11 months. Two type 1
endovascular leaks required a secondary endovascular intervention.
Comment: In expert hands, total arch replacement with traditional
techniques frequently requires deep hypothermic circulatory rest, often a
two-stage procedure, and has perioperative death or stroke rates approach-
ing 15% (Ann Thorac Surg 2007;83 [suppl]:815-8). Comparatively, the
current results with hybrid procedures seem improved. The approach has
several potential technical advantages. Cardiopulmonary bypass is generally
not needed, and simultaneous treatment of arch and descending thoracic
lesions, which previously required a two-stage repair with elephant trunk
procedures, can be performed sooner, given the smaller magnitude of the
endovascular component. The authors note that using existing Dacron
grafts for proximal landing zonesmaybe problematic. Type 1 endoleak for such
